is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Tell us about your organisation and its journey to date.
Since its establishment in 2012, Vazyme has been dedicated to our mission, "Science and Technology Make a Healthier Life" to focus on enzyme and protein technology innovation. Vazyme gradually enter the field of life science, biomedicine, and in vitro diagnostics. Now Vazyme has become the leading company providing life science reagents and molecular diagnostic materials in China.
How has the organisation evolved to address the challenges of an ever-changing healthcare sector? Please list some accomplishments.
To help humans overcome epidemics, tumours, and autoimmune diseases, we played an important role in the fight against the African swine flu and COVID-19. We are among the first to roll out COVID-19 testing solutions. As of Q2 2022, we provided detection kit manufacturers with key raw materials that could be used for about 2.07 billion tests.
Give us an insight into your portfolio and solutions targeted at the Middle East region.
In the Middle East region, we mainly promote COVID-19 detection products, molecular biology research reagents, NGS reagents and molecular diagnostic materials.
Tell us about your recent and upcoming investments and partnerships in this field.
In 2020, we launched a solution for COVID-19 detection including nucleic acid, antigen and antibody detection. Recently, we finished vaccine development and the evaluation of related products and services, which could greatly accelerate the rapid development and marketing of various vaccines, including mRNA vaccines. Vazyme has supported the development of several vaccines in China.
What will you be showcasing at Medlab Middle East 2023?
In addition to our COVID-19 diagnostic solutions, we will also exhibit molecular biological research reagents, NGS reagents, molecular diagnostic materials, biomedical R&D solutions and POCT products in this exhibition.
In addition to the above, what opportunities are you looking forward to at the upcoming event?
We hope to find partners and customers in life science research reagents, high-throughput sequencing reagents and molecular diagnostic materials.
Please tell us about your plans for the year 2023.
We will put more strength to expand overseas markets in 2023 and introduce more competitive products to the international market. Vazyme expects to provide better scientific research and medical products and services for people in other countries.
Anything else you would like to add?
This is Vazyme’s third time at Medlab Middle East. We appreciate all the recognition and support and wish Medlab Middle East 2023 every success. You are more than welcome to meet Vazyme and know more about what we do at Dubai World Trade Centre in Dubai on February 6, 2023.